RxDoctor Payments Data

Tong Liu, MD

Cardiovascular Disease · Ocala, FLNPI 1922259399

Payments from drug & device makers

$5,676in general payments, 2019–2025

Across 264 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$687
  • AstraZeneca$679
  • Amgen$597
  • Abbott$581
  • Pfizer$403
  • Esperion Therapeutics, Inc.$357
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,656100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,676 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$778,439
Medicare patients
1,331
Services billed
7,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban568$718,526
EntrestoSacubitril/Valsartan142$198,804
XareltoRivaroxaban150$183,071
Repatha SureclickEvolocumab86$76,424
NexlizetBempedoic Acid/Ezetimibe49$39,640
FarxigaDapagliflozin Propanediol14$19,987
BrilintaTicagrelor13$16,372
Metoprolol Succinate696$9,281
Praluent PenAlirocumab14$7,890
Amiodarone Hcl175$7,738
EdarbiAzilsartan Medoxomil18$6,958
Diltiazem 12hr ErDiltiazem Hcl24$5,558
Ranolazine ErRanolazine39$4,816
Midodrine Hcl48$4,611
Prasugrel Hcl29$4,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$403$718,526568 claims
NovartisEntresto$687$198,804142 claims
Johnson & JohnsonXarelto$231$183,071150 claims
Esperion Therapeutics, Inc.Nexlizet$357$39,64049 claims
AstraZenecaFarxiga, Brilinta$679$36,35927 claims
Arbor Pharmaceuticals, Inc.Edarbi$42$6,95818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →